SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:gup.ub.gu.se/55868"
 

Search: onr:"swepub:oai:gup.ub.gu.se/55868" > The effect of losar...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Fossum, E. (author)

The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study

  • Article/chapterEnglish2005

Publisher, publication year, extent ...

  • Elsevier BV,2005

Numbers

  • LIBRIS-ID:oai:gup.ub.gu.se/55868
  • https://gup.ub.gu.se/publication/55868URI
  • https://doi.org/10.1016/j.jacc.2005.05.060DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-6141URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:1931426URI

Supplementary language notes

  • Language:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • OBJECTIVES: We conducted a subgroup analysis in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study to determine whether aspirin interacted with the properties of losartan, an angiotensin-II receptor antagonist. BACKGROUND: Negative interactions between angiotensin-converting enzyme inhibitors and aspirin have been reported. There are no data reported from clinical trials about possible interactions between angiotensin-II receptor antagonists and aspirin. METHODS: The LIFE study assigned 9,193 patients with hypertension and left ventricular hypertrophy (LVH) to losartan- or atenolol-based therapy for a mean of 4.7 years, with 1,970 (21.4%) taking aspirin at baseline. The primary composite end point (CEP) included cardiovascular death, stroke, and myocardial infarction (MI). The present cohort was stratified by aspirin use at baseline. RESULTS: Blood pressures were reduced similarly in the losartan with aspirin (n = 1,004) and atenolol with aspirin (n = 966) groups. The CEP was reduced by 32% (95% confidence interval 0.55 to 0.86, p = 0.001) with losartan with aspirin compared to atenolol with aspirin, adjusted for Framingham risk score and LVH. The test for treatment versus aspirin interaction, excluding other covariates, was significant for the CEP (p = 0.016) and MI (p = 0.037). CONCLUSIONS: There was a statistical interaction between treatment and aspirin in the LIFE study, with significantly greater reductions for the CEP and MI with losartan in patients using aspirin than in patients not using aspirin at baseline. Further studies are needed to clarify whether this represents a pharmacologic interaction or a selection by aspirin use of patients more likely to respond to losartan treatment.

Subject headings and genre

  • Adrenergic beta-Antagonists/adverse effects/*therapeutic use
  • Aged
  • Angiotensin II Type 1 Receptor Blockers/adverse effects/*therapeutic use
  • Aspirin/adverse effects/*therapeutic use
  • Atenolol/adverse effects/*therapeutic use
  • Drug Interactions
  • Drug Therapy
  • Combination
  • Female
  • Humans
  • Hypertension/complications/*drug therapy
  • Hypertrophy
  • Left Ventricular/complications/*drug therapy
  • Losartan/adverse effects/*therapeutic use
  • Male
  • Treatment Outcome
  • Adrenergic beta-Antagonists/adverse effects/*therapeutic use

Added entries (persons, corporate bodies, meetings, titles ...)

  • Moan, A. (author)
  • Kjeldsen, S. E. (author)
  • Devereux, R. B. (author)
  • Julius, S. (author)
  • Snapinn, S. M. (author)
  • Edelman, J. M. (author)
  • de Faire, U.Karolinska Institutet (author)
  • Fyhrquist, F. (author)
  • Ibsen, H. (author)
  • Kristianson, K.Karolinska Institutet (author)
  • Lederballe-Pedersen, O. (author)
  • Lindholm, Lars HUmeå universitet,Allmänmedicin(Swepub:umu)lali0003 (author)
  • Nieminen, M. S. (author)
  • Omvik, P. (author)
  • Oparil, S. (author)
  • Wedel, H. (author)
  • Dahlöf, Björn,1953Gothenburg University,Göteborgs universitet,Hjärt-kärlinstitutionen,Cardiovascular Institute(Swepub:gu)xdahbj (author)
  • Karolinska InstitutetAllmänmedicin (creator_code:org_t)

Related titles

  • In:J Am Coll Cardiol: Elsevier BV46:5, s. 770-50735-1097

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view